NL-OMON31563撤回不适用
Clinical evaluation of the Gen2 irrigated ablation catheter for the treatment of cardiac arrhythmias - Gen2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 103
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Be between eighteen and eighty years of age;
- •Be scheduled for an atrial fibrilation ablation procedure;
- •Be able to undergo contrast-enhanced MRI imaging;
- •Have a cardiac CT or MRI scan within a 6 months time window prior to the planned procedure ;
- •Be willing and able to sign the study specific consent form;
- •Be willing and able to fulfill study requirements (including study follow-up visits);
- •Have a negative pregnancy test for females in case of doubt about a possible pregnancy and
- •Have documented paroxysmal or persistent atrial fibrillation (by electrocardiogram (ECG); trans-telephonic monitor (TTM); Holter monitor or telemetry strip)
排除标准
- •Have evidence of or is currently receiving treatment for infection (local or systemic);
- •Have evidence of LA thrombus prior to procedure;
- •Be hypercoaguable (unable to tolerate heparin anticoagulation therapy) during the procedure;
- •Have history of embolic event(s). (e.g., cerebrovascular accident, pulmonary embolism, transient ischemic attack, etc.);
- •Have experienced a myocardial infarction <=3 months prior to the study procedure;
- •Have recent history (<=3 months) of cardiac surgery; including device implants (e.g. pacemaker, implantable cardiac defibrillator, etc.);
- •Have significant coronary heart disease or heart failure (i.e. unstable angina pectoris and/or uncontrolled congestive heart failure resulting in NYHA Class III or IV) at the time of enrollment, except in cases where the NYHA Class III diagnosis is due to sustained AFL with rapid ventricular response;
- •Have history of any previous cardiac ablation for atrial fibrillation;
- •Have prosthetic heart valve or valvular heart disease requiring surgical intervention;
- •Have a pacemaker or ICD leads in or around the coronary sinus or coronary vasculature;
- •Be awaiting cardiac transplant or other cardiac surgery within the following 12 months;
- •Have significant pulmonary disease, or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms;
- •Have any condition for which the investigator feels it is unsafe for the subject to undergo an invasive EP catherization;
- •Have any condition for which the subject*s life expectancy is less than 12 months and
- •Be currently participating in another investigational study.
研究者
相似试验
招募中
不适用
Evaluation of ablation in the treatment of arrhythmiaSupraventricular tachyarrythmia.I47.1Supraventricular tachycardiaIRCT20160926029976N5Vice Chancellor For Research, Babol University Of Medical Sciences80
已完成
2 期
An evaluation of Focal ablation therapy using High-Intensity Focused Ultrasound in the treatment of localised adenocarcinoma of the prostateocalised prostate cancerMalignant neoplasm of the prostateCancerISRCTN69304414niversity College London Hospitals NHS Foundation Trust (UK)42
进行中（未招募）
Unknown
A Study of the Outcome of Catheter Ablation for Atrial Fibrillation Complicated by Hypertrophic CardiomyopathyHypertrophioc cardiomyopathyHypertrophic cardiomyopathy, atrial fibrillationD002312JPRN-jRCT1020230057Kinjo Takahiko60
已完成
不适用
Efficacy and Safety of Low-voltage Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients with Persistent Atrial FibrillatioPersistent atrial fibrillationJPRN-UMIN000035940Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine340
已完成
不适用
Clinical Investigation of the VytronUS Ablation System for Treatment <br>of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillatiorecurrent paroxysmal atrial fibrillation10007521Cardiac arrhythmiaNL-OMON46588VytronUS, Inc.20